Showing 1 - 8 results of 8 for search '"Pharmacokinetics and pharmacodynamics"', čas poizvedbe: 0.02s Refine Results
  1. 1
    Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

    Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cance... od Aurelius Omlin (14971513)

    Izdano 2025
    Teme:
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

    Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer od Aurelius Omlin (14971513)

    Izdano 2025
    Teme:
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates od Evan C. Chen (15054014)

    Izdano 2025
    Teme:
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates od Evan C. Chen (15054014)

    Izdano 2025
    Teme:
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates od Evan C. Chen (15054014)

    Izdano 2025
    Teme:
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates od Evan C. Chen (15054014)

    Izdano 2025
    Teme:
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates od Evan C. Chen (15054014)

    Izdano 2025
    Teme:
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates od Evan C. Chen (15054014)

    Izdano 2025
    Teme:
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: